New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
07:44 EDTAZN, SLXP, NKTR, PGNXFDA Anesthetic & Analgesic Drug Products Advisory Committee holds a meeting
The Committee reviews opioid antagonists being developed for opioid induced constipation including Progenics' and Salix Pharmaceuticals' Subcutaneous RELISTOR and Nektar Therapeutics and AstraZeneca's Naloxegol in a meeting being held at FDA Silver Spring, Maryland offices on June 12 at 8 am. Webcast Link
News For AZN;NKTR;SLXP;PGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 17, 2014
06:43 EDTAZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
November 16, 2014
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
November 14, 2014
14:53 EDTAZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:14 EDTAZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.
November 13, 2014
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
11:17 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:53 EDTNKTRLeerink to hold a tour
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:20 EDTSLXPSalix risk/reward remains favorable, says Leerink
Subscribe for More Information
06:14 EDTSLXPSalix risk/reward now 'more interesting,' says Deutsche Bank
Subscribe for More Information
November 10, 2014
10:04 EDTSLXPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded at Oppenheimer... American Eagle (AEO) downgraded to Neutral from Buy at B. Riley... BP (BP) downgraded to Neutral from Overweight at JPMorgan... Callon Petroleum (CPE) downgraded to Neutral from Buy at SunTrust... EP Energy (EPE) downgraded to Hold from Buy at Deutsche Bank... Eaton Vance (EV) downgraded at Sterne Agee... Ecopetrol (EC) downgraded to Underperform from Sector Perform at RBC Capital... General Mills (GIS) downgraded to Sector Perform from Outperform at RBC Capital... Genworth (GNW) downgraded to Market Perform from Outperform at Keefe Bruyette... MasTec (MTZ) downgraded to Hold from Buy at BB&T... Ocean Rig UDW (ORIG) downgraded to Neutral from Buy at Guggenheim... Performant Financial (PFMT) downgraded at Morgan Stanley... Petrobras (PBR) downgraded to Market Perform from Outperform at Cowen... R.R. Donnelley (RRD) downgraded to Hold from Buy at Benchmark Co.... Rex Energy (REXX) downgraded to Market Perform from Outperform at BMO Capital... Salix (SLXP) downgraded to Neutral from Buy at Mizuho... Siemens (SIEGY) downgraded to Neutral from Overweight at JPMorgan... Solazyme (SZYM) downgraded to Equal Weight from Overweight at Morgan Stanley... Stonegate Mortgage (SGM) downgraded to Market Perform at FBR Capital... Syngenta (SYT) downgraded to Neutral from Overweight at HSBC... ViaSat (VSAT) downgraded to Hold from Buy at Needham... Vistaprint (VPRT) downgraded to Neutral from Buy at SunTrust... Walter Investment (WAC) downgraded at Sterne Agee... WesBanco (WSBC) downgraded to Market Perform from Outperform at Keefe Bruyette... Whiting USA Trust II (WHZ) downgraded to Underperform at Raymond James... Wipro (WIT) downgraded to Sell from Buy at UBS... XOMA (XOMA) downgraded to Neutral from Buy at Ladenburg... Yanzhou Coal (YZC) downgraded to Sell from Hold at Deutsche Bank.
09:06 EDTSLXPSalix shares still poised to rise significantly, says Sterne Agee
Subscribe for More Information
08:29 EDTSLXPSalix price target lowered to $127 from $181 at Cantor
Cantor cut its price target on Salix after the company reported weaker than expected results, sharply cut its 2014 guidance and disclosed that it had stocked retailers with nine months of a number of key brands. However, the firm keeps a Buy rating on the stock based on valuation and its belief that the company may remain a takeover target.
06:40 EDTSLXPSalix downgraded to Neutral from Buy at Mizuho
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use